SecBot SecBot
PRESS-RELEASE ·Filed Sep 11, 2026

LLY

Eli Lilly and Company
BULLISH
Impact 5/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition is a modest strategic positive for Lilly's long-term neuroscience pipeline but immaterial to near-term financials given the early-stage nature of the assets and undisclosed deal size. Monitor for clinical readouts of BPL-003 in treatment-resistant depression, which could drive future value, but no immediate catalyst is expected.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1,115.70
T+0 close · Sep 11, 2026 · via day close
Latest settled
+5.70%
T+20 · $1,179.27 · next T+60 in 20d
Vs SPY
+3.83%
α at T+20
Latest observation
+32.62%
T+46 · FF3 residual α
  1. T+0 · Sep 11 $1,115.70entry
  2. T+1 · 2mo ago +2.02%α +2.47% · $1,138.28
  3. T+5 · 2mo ago +3.34%α +3.56% · $1,152.93
  4. T+20 · 6w ago +5.70%α +3.83% · $1,179.27
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental health conditions, including its lead candidate BPL-003 for treatment-resistant depression. The deal expands Lilly's neuroscience pipeline into a novel, rapid-acting therapeutic class for a large unmet need, though no financial terms were disclosed and the assets remain early-stage with clinical and regulatory risk. The acquisition is a strategic pipeline addition for a $1T+ mega-cap, making it a modest positive rather than a transformative event for the stock.

Key Facts

  • Lilly completed the acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company.
  • AtaiBeckley's lead program is BPL-003, a rapid-acting neuroplastogen for treatment-resistant depression.
  • The transaction was approved by AtaiBeckley shareholders at a special meeting prior to closing.
  • No financial terms of the acquisition were disclosed in the press release.

Financial Impact

Undisclosed deal value; pipeline expansion for Lilly's neuroscience division with no immediate revenue impact.

pipeliner&d expense

Risk Factors

  • BPL-003 is in clinical-stage development and faces risk of clinical trial failure or regulatory setbacks.
  • Undisclosed deal terms create uncertainty about the financial commitment and potential dilution.
  • Treatment-resistant depression is a competitive space with multiple novel mechanisms in development.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302876428

Track record

23 reports on LLY

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +31.53% at T+60 after the Apr 16, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Oct 30, 202617d ago 144 Neutral 3/10 Entry $1,417.54 to $1,410.99 Now $1,431.67 +1.00% ▼ −0.46% +0.02% vs SPY
  2. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $1,373.70 to $1,417.54 Now $1,431.67 +4.22% ▲ +3.19% +4.96% vs SPY
  3. Oct 26, 202621d ago Press Release Neutral 2/10 Entry $1,279.14 to $1,281.91 Now $1,431.67 +11.92% ▲ +0.22% −0.34% vs SPY
  4. Oct 26, 202622d ago Court Ruling Neutral 3/10 Entry $1,281.91 to $1,288.30 Now $1,431.67 +11.68% ▲ +0.50% +0.15% vs SPY
  5. Oct 19, 202628d ago SC 13G/A Neutral 3/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
  7. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $1,251.61 to $1,257.03 Now $1,431.67 +14.39% ▲ +0.43% +1.54% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 3/10 Entry $1,188.72 to $1,169.60 Now $1,431.67 +20.44% ▼ −1.61% −1.19% vs SPY
  9. Sep 11, 20269w ago Press Release Bullish 5/10 Viewing Entry $1,115.70 to $1,138.28 Now $1,431.67 +28.32% ▲ +2.02% +2.47% vs SPY
  10. Sep 8, 202610w ago Court Ruling Neutral 4/10 Entry $1,124.21 to $1,123.00 Now $1,431.67 +27.35% ▼ −0.11% +0.49% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026